Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
The body thrives when we treat it as one connected, intelligent system
To view or add a comment, sign in New AusPAR for Adzynma is a recombinant ADAMTS13 enzyme replacement therapy that has been approved for the treatment of ADAMTS13 deficiency in patients with congenital thrombotic thrombocytopenic purpura (cTTP)
Still, the analysts predicted that Ozempic, Wegovy, and Rybelsus (semaglutide) maker Novo Nordisk and Eli Lilly, which developed Zepbound and Mounjaro (tirzepatide), will maintain two-thirds of the market by 2031 due to their first-mover advantages. Other competitors are expected to take a combined $70 billion of the GLP-1 market, the study read
The SUSTAIN-6 trial for semaglutide (3,297 patients, median 2.1 years), LEADER trial for liraglutide (9,340 patients, median 3.8 years), and REWIND trial for dulaglutide (9,901 patients, median 5.4 years) all included comprehensive adverse event monitoring
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
Please note the interest rate is subject to change
US$ 21.59
US$ 27.38
US$ 26.90
US$ 26.76
US$ 22.41
US$ 26.89
US$ 24.60
US$ 24.88
US$ 23.48
US$ 22.47
US$ 27.96
